368 related articles for article (PubMed ID: 32096671)
1. Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis.
Phan K; Phan S; Shumack S; Gupta M
J Dermatolog Treat; 2022 Feb; 33(1):173-177. PubMed ID: 32096671
[TBL] [Abstract][Full Text] [Related]
2. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
Liu LY; Strassner JP; Refat MA; Harris JE; King BA
J Am Acad Dermatol; 2017 Oct; 77(4):675-682.e1. PubMed ID: 28823882
[TBL] [Abstract][Full Text] [Related]
3. The use of Janus kinase inhibitors and narrowband ultraviolet B combination therapy in non-segmental vitiligo.
Yousefian F; Yadlapati S; Browning JC
J Cosmet Dermatol; 2023 Mar; 22(3):1105-1107. PubMed ID: 36440703
[TBL] [Abstract][Full Text] [Related]
4. The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature.
Relke N; Gooderham M
J Cutan Med Surg; 2019; 23(3):298-306. PubMed ID: 30902022
[TBL] [Abstract][Full Text] [Related]
5. Protocol for a systematic review and meta-analysis on Janus kinase inhibitors in the management of vitiligo.
Pranić S; Pulumati A; Vuković D
Syst Rev; 2024 Apr; 13(1):110. PubMed ID: 38641831
[TBL] [Abstract][Full Text] [Related]
6. Micro - Focused Phototherapy Associated To Janus Kinase Inhibitor: A Promising Valid Therapeutic Option for Patients with Localized Vitiligo.
Gianfaldoni S; Tchernev G; Wollina U; Roccia MG; Fioranelli M; Lotti J; Rovesti M; Satolli F; Valle Y; Goren A; Tirant M; Situm M; Kovacevic M; França K; Lotti T
Open Access Maced J Med Sci; 2018 Jan; 6(1):46-48. PubMed ID: 29483979
[TBL] [Abstract][Full Text] [Related]
7. The effect of NB-UVB on noncultured melanocyte and keratinocyte transplantation in treatment of generalized vitiligo using two different donor-to-recipient ratios.
Tawfik YM; Abd Elazim NE; Abdel-Motaleb AA; Mohammed RAA; Tohamy AMA
J Cosmet Dermatol; 2019 Apr; 18(2):638-646. PubMed ID: 30280485
[TBL] [Abstract][Full Text] [Related]
8. Biologic and targeted therapeutics in vitiligo.
Karagaiah P; Schwartz RA; Lotti T; Wollina U; Grabbe S; Goldust M
J Cosmet Dermatol; 2023 Jan; 22(1):64-73. PubMed ID: 35029034
[TBL] [Abstract][Full Text] [Related]
9. Effect of narrow band ultraviolet B phototherapy as monotherapy or combination therapy for vitiligo: a meta-analysis.
Li R; Qiao M; Wang X; Zhao X; Sun Q
Photodermatol Photoimmunol Photomed; 2017 Jan; 33(1):22-31. PubMed ID: 27696531
[TBL] [Abstract][Full Text] [Related]
10. JAK inhibitors in vitiligo: what they hit and what they miss - an immunopathogenesis based exposition of existing evidence.
Sardana K; Muddebihal A; Khurana A
Expert Rev Clin Pharmacol; 2023; 16(12):1221-1227. PubMed ID: 37982238
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcome and persistence of repigmentation from narrow-band ultraviolet B phototherapy in vitiligo.
Silpa-Archa N; Weerasubpong P; Junsuwan N; Yothachai P; Supapueng O; Wongpraparut C
J Dermatolog Treat; 2019 Nov; 30(7):691-696. PubMed ID: 30474443
[No Abstract] [Full Text] [Related]
12. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.
Qi F; Liu F; Gao L
Front Immunol; 2021; 12():790125. PubMed ID: 34868078
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child.
Olamiju B; Craiglow BG
Pediatr Dermatol; 2020 Jul; 37(4):754-755. PubMed ID: 32255214
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of local prostaglandin analogues for vitiligo treatment: a systematic review and meta-analysis.
Chang HC; Guo SP
Expert Rev Clin Pharmacol; 2022 Mar; 15(3):341-349. PubMed ID: 35473496
[TBL] [Abstract][Full Text] [Related]
15. Topical Tofacitinib: A Janus Kinase Inhibitor for the Treatment of Vitiligo in an Adolescent Patient.
Berbert Ferreira S; Berbert Ferreira R; Neves Neto AC; Assef SMC; Scheinberg M
Case Rep Dermatol; 2021; 13(1):190-194. PubMed ID: 34703426
[TBL] [Abstract][Full Text] [Related]
16. JAK inhibitors for the treatment of vitiligo.
Inoue S; Suzuki T; Sano S; Katayama I
J Dermatol Sci; 2024 Mar; 113(3):86-92. PubMed ID: 38326166
[TBL] [Abstract][Full Text] [Related]
17. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
Huang MY; Armstrong AW
Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):30-40. PubMed ID: 38031699
[TBL] [Abstract][Full Text] [Related]
18. A review of JAK and IL-23 inhibitors to treat vitiligo.
Lee H; Cowan TL; Daniel BS; Murrell DF
Australas J Dermatol; 2023 May; 64(2):204-212. PubMed ID: 36810815
[TBL] [Abstract][Full Text] [Related]
19. Disorders of Hypopigmentation.
Dina Y; McKesey J; Pandya AG
J Drugs Dermatol; 2019 Mar; 18(3):s115-s116. PubMed ID: 30909355
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of 308-nm Monochromatic Excimer Lamp Versus Other Phototherapy Devices for Vitiligo: A Systematic Review with Meta-Analysis.
Lopes C; Trevisani VF; Melnik T
Am J Clin Dermatol; 2016 Feb; 17(1):23-32. PubMed ID: 26520641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
